Hereditary Angioedema Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035

Market Lifecycle Stage

The global hereditary angioedema market is currently in the growth stage of its lifecycle. This phase is characterized by an increasing number of treatment options, including novel biologic therapies and prophylactic treatments, which are gaining regulatory approvals. The market is experiencing expansion driven by the rising awareness of hereditary angioedema, improved diagnostic methods, and the introduction of advanced therapies such as C1 esterase inhibitors and bradykinin receptor antagonists. Additionally, the growing focus on personalized medicine and preventive care is contributing to the growth of the market. Although challenges such as high treatment costs and a limited patient population remain, the ongoing innovation in treatment options and expanding market access are expected to sustain the market’s growth in the coming years.

Impact

Increasing demand for hereditary angioedema therapies is anticipated to support the growth of the global hereditary angioedema market during the forecast period 2025-2035.
The global hereditary angioedema market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

Market Segmentation:

Segmentation 1: by Therapy Type

C1-esterase inhibitor
Bradykinin B2 receptor antagonist
Kallikrein inhibitor
Others

Segmentation 2: by Region

North America
Europe
Asia-PacificNorth America is expected to dominate the global hereditary angioedema market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global hereditary angioedema market.

Recent Developments

Regulatory Activities: In February 2025, EMA approved an additional 2 mL pre-filled pen option for TAKHZYRO (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with hereditary angioedema (HAE).
Regulatory Activities: In February 2025, CSL Behring secured regulatory approval in Japan for Andembry (garadacimab) subcutaneous injection 200mg Pens for the prevention of acute hereditary angioedema attacks.
Regulatory Activities: In January 2025, Japan’s Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation to KalVista Pharmaceuticals, Inc.’s sebetralstat.
Regulatory Activities: In November 2024, the FDA accepted the new drug application for Ionis Pharmaceuticals’ donidalorsen for the prophylactic treatment of hereditary angioedema.

Demand – Drivers and Limitations

The following are the drivers for the global hereditary angioedema market:

Increasing Awareness and Early Diagnosis
Continuous Advancements in Treatment Options
Improved Genetic Testing and Diagnosis
Increasing Prevalence of Hereditary Angioedema

The global hereditary angioedema market is expected to face some limitations, too, due to the following challenges:

High Treatment Costs
Challenges in Accessing Treatments in Developing Regions

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Product launches and innovations in the global hereditary angioedema market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Ionis Pharmaceutical, Takeda, and CSL Behring, have been involved in the development of therapies for hereditary angioedema.

Competitive Strategy: Enterprises led by market leaders in the global hereditary angioedema market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

Adverum Biotechnologies, Inc.
Attune Pharmaceuticals
BioCryst Pharmaceuticals
CSL Behring
Ionis Pharmaceuticals, Inc.
KalVista Pharmaceuticals
Octapharma
Pharming Group
Takeda Pharmaceutical Company Limited

*PDF email from publisher allows for 1-3 users, with permission to print*

Please Note: It will take 1-5 business days to complete the report upon order confirmation.